NCT04332653 2026-03-09
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
Phase 1/2 Completed
Clinical Trials
12 trialsNCT05075603 2025-10-23
Relapsed/Refractory Large B-cell Lymphoma With NT-I7 Post-CD19 CAR T-cell Therapy
NeoImmuneTech
Phase 1 Completed
NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
NCT04594811 2024-08-16
NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma
NeoImmuneTech
Phase 1 Terminated
NCT06344715 2024-04-03
Phase 1 Study Evaluating Safety and Tolerability of SL-T10, GX-I7, and Pembrolizumab Triple Combination in mCRPC.
SL VAXiGEN
Phase 1 Recruiting
NCT03752723 2024-03-05
KEYNOTE-899
Genexine, Inc.
Phase 1/2 Completed
NCT04984811 2024-03-05
NT-I7 in Combination With Atezolizumab in Previously Untreated, PD-L1-expressing, Locally Advanced or Metastatic NSCLC
NeoImmuneTech
Phase 2 Active not recruiting
NCT05191784 2023-06-12
GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients
Genexine, Inc.
Phase 2 Unknown
NCT04065087 2022-03-17
Efficacy and Safety Study of GX-I7 Plus Adjuvant Temozolomide Combination in Patients With Newly Diagnosed Glioblastoma
Genexine, Inc.
Phase 1/2 Withdrawn
NCT04289155 2022-03-17
Individual Patient Compassionate Use of GX-I7
Genexine, Inc.
No longer available
NCT03733587 2020-05-14
GX-I7 With Cyclophosphamide in Patients With Metastatic or Recurrent Solid Tumors
Genexine, Inc.
Phase 1 Completed
NCT03478995 2020-05-11
Study to Evaluate Safety and Tolerability of GX-I7 in Patients With Locally Advanced or Metastatic Solid Tumors
Genexine, Inc.
Phase 1 Completed